Chimeric Antigen Receptor T Cell Therapy and Its Significance in Multiple Myeloma.

Padda, Jaskamal; Khalid, Khizer; Zubair, Ujala; Peethala, Mounika M; Kakani, Varsha; Goriparthi, Lakshmi; Almanie, Abdulelah H; Cooper, Ayden Charlene; Jean-Charles, Gutteridge

Padda, Jaskamal; Khalid, Khizer; Zubair, Ujala; Peethala, Mounika M; Kakani, Varsha; Goriparthi, Lakshmi; Almanie, Abdulelah H; Cooper, Ayden Charlene; Jean-Charles, Gutteridge.

Afiliação

Padda J; Internal Medicine, JC Medical Center, Orlando, USA.
Khalid K; Internal Medicine, Avalon University School of Medicine, Willemstad, CUW.
Zubair U; Internal Medicine, JC Medical Center, Orlando, USA.
Peethala MM; Family Medicine, Dow University of Health Sciences, Karachi, PAK.
Kakani V; Internal Medicine, Rajeev Gandhi Institute of Medical Sciences, Kadapa, IND.
Goriparthi L; Internal Medicine, JC Medical Center, Orlando, USA.
Almanie AH; Internal Medicine, Kakatiya Medical College, Warangal, IND.
Cooper AC; Internal Medicine, JC Medical Center, Orlando, USA.
Jean-Charles G; Internal Medicine, JC Medical Center, Orlando, USA.

Cureus ; 13(6): e15917, 2021 Jun.

Article em En | MEDLINE | ID: mdl-34322356

Palavras-chave

bcma; car t cells; cd19; cd38; chimeric antigen receptor t-cell therapy; multiple myeloma; syndecan-1 (cd138)

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article